Eli Lilly want to double operation in Brazil until 2020

Until 2020, the American drugmaker Eli Lilly intends to double the size of the brazilian operation, in number of patients, and achieve the leadership in the world and domestic markets of insulins. To this end, remained firmly on the path of increnental and radical innovation-unlike many of its peers, is not evaluating opportunities for acquisition or merger to boost business growth-and aims to reach 2023 having released 20 medicines and 25 new indications for existing products.
Specifically in the Brazilian market, Lilly wants to get about 2,000,000 patients served (front of 1.1 million in the last 12 months) and between two and three products per year over the next five years. In the meantime, the President of pharmaceutical Value in Brazil, Julio Gay-Ger, the greater chance of launching products of the new wave of pharmaceutical innovation is in the country.
"After China, Brazil is the most relevant market between the emerging", he says. Present in more than 120 countries, the company classifies as emerging markets outside Europe, United States and Japan.
From the perspective of the pharmaceutical, the current pipeline is one of the richest in its history, with seven in the third and final phase of development, 12:00 pm phase two and 19 more in the first phase. On average, each new molecule consumes between $ 800,000,000 and $ 1.3 billion while being developed and may take 15 years to reach the market.
"Lilly is the 11th or 12th largest in the world with a clear strategy of investment in innovation", says the Executive. Last year, had net sales of about $ 20 billion--more than half in the United States, including Puerto Rico, with net income of $ 2.5 billion and $ 4.8 billion invested in research. Partnerships with other large Drugmakers are also part of the company''s tactics, which in 2011, for example, announced an alliance with the German Boehringer Ingelheim in the area of diabetes.
The Brazil has started to receive innovative medicines of the new crop of releases. The first was the Cyramza (ramicirumabe), a monoclonal antibody indicated for the treatment of gastric cancer, approved by the national agency of sanitary surveillance (Anvisa) in February this year. The second should be the Trulicity (dulaglutida), for glycemic control in patients with diabetes and weekly usage 2.
The area of diabetes is one of the main focuses of attention from the drug company, which is working to have a full portfolio of products. One of the main releases, in this sense, it is a basal insulin analog, which must reach the country in the coming years. Today, Lilly has a strong presence in human insulin sales in the country, with leadership in the people''s Pharmacy Program, and in similar pós-refeição insulins. "We will be the first company with presence in every stage. This is our strategy for the leadership, "he says.
Another area of focus of the company, Oncology focuses today about 40% of the pipeline of new drugs. In immuno-Oncology, the pharmacist will have five molecules in clinical trials still in 2016 and up to 11 to the end of 2018. At this point, the Brazil participates in clinical trials for use of Cyramza in other types of tumors and have growing presence in the research conducted by the multinational, which carries out tests since 1995 in the country, with more than 200 studies developed.
The arrival of new medicinal products to the domestic market and expansion of sales led to the need for new investment in factory in Brooklyn, a neighborhood on the South side of São Paulo. Right now, says Gay-Ger, Lilly are applying R$ 15,000,000 in its manufacturing unit, especially in the area of packaging.
Today, are produced in the country the antipressivo Prozac, Zyprexa (for schizophrenia), Cialis (erectile dysfunction) and Evista (for the prevention and treatment of osteoporosis). The other products are packed in the country. "With more clinical research, Lilly will bring more releases and this should generate new investment in manufacturing," he says.